Pfizer announced that the Federal Court of Appeal of Canada has upheld a patent that prevents generic-drug maker Ranbaxy Laboratories Ltd. from marketing a copy of Lipitor before the patent lapses in July 2010. A Pfizer representative said the ruling helps motivate drugmakers "to make the significant high-risk investments necessary to develop new life-saving medicines." Ranbaxy may ask the Supreme Court of Canada to review the decision.

Related Summaries